EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Noxopharm's Enterprise Value is $4.83 Mil.
Noxopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.10 Mil. Therefore, Noxopharm's EV-to-FCF for today is -1.18.
The historical rank and industry rank for Noxopharm's EV-to-FCF or its related term are showing as below:
NOXOF'
s EV-to-FCF Range Over the Past 10 Years
Min: -16.49 Med: 0 Max: 0.17
Current: -1.2
During the past 7 years, the highest EV-to-FCF of Noxopharm was 0.17. The lowest was -16.49. And the median was 0.00.
NOXOF's EV-to-FCF is ranked worse than 100% of 390
companies
in the Biotechnology industry
Industry Median: 6.305
vs NOXOF: -1.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-14), Noxopharm's stock price is $0.03.
Noxopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.028. Therefore, Noxopharm's PE Ratio for today is At Loss.
Noxopharm EV-to-FCF Historical Data
The historical data trend for Noxopharm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Noxopharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noxopharm's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noxopharm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Noxopharm's EV-to-FCF falls into.
Noxopharm's current Enterprise Value is $4.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Noxopharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.10 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Noxopharm (OTCPK:NOXOF) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Noxopharm's share price for today is $0.03.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Noxopharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.028.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Noxopharm EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Noxopharm's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NOXOF has been successfully added to your 